hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10

Xi,Hao; Li,Lu; Du,Juan; An,Ran; Fan,Rong; Lu,Jing; Wu,Yin-Xiang; Wu,Shu-Xie; Hou,Jian; Zhao,Li-Ming

doi:10.3892/or.2016.5318

hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10

Authors:
- Hao Xi
- Lu Li
- Juan Du
- Ran An
- Rong Fan
- Jing Lu
- Yin-Xiang Wu
- Shu-Xie Wu
- Jian Hou
- Li-Ming Zhao
View Affiliations

Affiliations: Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, P.R. China, Department of Respiratory Diseases, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, P.R. China, Grade Eight-Year Program, Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: December 14, 2016 https://doi.org/10.3892/or.2016.5318
Pages: 961-968

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although bortezomib (BTZ) remains a first-line agent for multiple myeloma (MM) therapy, the development of BTZ resistance has become an indicator of poor prognosis in MM patients. It is thus urgent to develop strategies to restore the vulnerability of MM to BTZ. This study demonstrated, for the first time, that UbcH10 is highly expressed in BTZ-resistant myeloma cell lines U-266/BTZ, NCI-H929/BTZ and RPMI-8226/BTZ, which is attributed to the inactivation of post-transcriptional control. The in-depth study revealed that during the development of BTZ resistance in these cells, the hsa-miR-631 levels were decreased, which resulted in the increased expression of the target gene UbcH10. We also found that the multiple drug-resistant protein MDR1 exhibited a positive correlation with UbcH10 due to the reduced ubiquitination of MDR1, which was caused by high UbcH10 expression. Following overexpression of miR-631, both BTZ sensitivity and BTZ-induced apoptosis were enhanced in the resistant cells. Meanwhile, resensitization by miR-631 overexpression was blocked by exogenous expression of UbcH10, which was not regulated by intracellular miR-631. In conclusion, the miR-631/UbcH10/MDR1 pathway is closely associated with the development of BTZ resistance in myeloma cells, and the overexpression of miR-631 can significantly improve BTZ sensitivity in resistant myeloma cells.

View Figures

View References

1	Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R and Crowley J: Treatment of multiple myeloma. Blood. 103:20–32. 2004. View Article : Google Scholar : PubMed/NCBI
2	Anderson KC: Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Canc Netw 11 (Suppl 5). 676–679. 2013.
3	Accardi F, Toscani D, Bolzoni M, Palma B Dalla, Aversa F and Giuliani N: Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling. BioMed Res Int. 2015:1724582015. View Article : Google Scholar : PubMed/NCBI
4	Adam Z, Sčudla V, Krejčí M, Cermáková Z, Pour L and Král Z: Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials. Vnitr Lek. 59:37–58. 2013.(In Czech). PubMed/NCBI
5	Adachi Y, Yoshio-Hoshino N and Nishimoto N: Gene therapy for multiple myeloma. Curr Gene Ther. 8:247–255. 2008. View Article : Google Scholar : PubMed/NCBI
6	Tétreault N and De Guire V: miRNAs: Their discovery, biogenesis and mechanism of action. Clin Biochem. 46:842–845. 2013. View Article : Google Scholar : PubMed/NCBI
7	Parker JS, Roe SM and Barford D: Molecular mechanism of target RNA transcript recognition by Argonaute-guide complexes. Cold Spring Harb Symp Quant Biol. 71:45–50. 2006. View Article : Google Scholar : PubMed/NCBI
8	Abe M: Multiple myeloma. Nihon Rinsho. 67:991–995. 2009.(In Japanese). PubMed/NCBI
9	Abdi J, Chen G and Chang H: Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms. Oncotarget. 4:2186–2207. 2013. View Article : Google Scholar : PubMed/NCBI
10	Abidi MH, Gul Z, Abrams J, Ayash L, Deol A, Ventimiglia M, Lum L, Mellon-Reppen S, Al-Kadhimi Z, Ratanatharathorn V, et al: Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. J Chemother. 24:167–172. 2012. View Article : Google Scholar : PubMed/NCBI
11	Abba M, Mudduluru G and Allgayer H: MicroRNAs in cancer: Small molecules, big chances. Anticancer Agents Med Chem. 12:733–743. 2012. View Article : Google Scholar : PubMed/NCBI
12	Azmi AS, Bao B and Sarkar FH: Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev. 32:623–642. 2013. View Article : Google Scholar : PubMed/NCBI
13	Allen KE and Weiss GJ: Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI
14	Akao Y, Khoo F, Kumazaki M, Shinohara H, Miki K and Yamada N: Extracellular disposal of tumor-suppressor miRs-145 and −34a via microvesicles and 5-FU resistance of human colon cancer cells. Int J Mol Sci. 15:1392–1401. 2014. View Article : Google Scholar : PubMed/NCBI
15	Bai H, Xu R, Cao Z, Wei D and Wang C: Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 585:402–408. 2011. View Article : Google Scholar : PubMed/NCBI
16	Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ, Huang X, Zhao J, Gu B, Zheng GX, Yang AG, et al: MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer. 135:1356–1368. 2014. View Article : Google Scholar : PubMed/NCBI
17	Fu D, Liu B, Zang LE and Jiang H: MiR-631/ZAP70: A novel axis in the migration and invasion of prostate cancer cells. Biochem Biophys Res Commun. 469:345–351. 2016. View Article : Google Scholar : PubMed/NCBI
18	Eldridge AG and O'Brien T: Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ. 17:4–13. 2010. View Article : Google Scholar : PubMed/NCBI
19	Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M and Nakagawara A: UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 63:4167–4173. 2003.PubMed/NCBI
20	Lin J, Raoof DA, Wang Z, Lin MY, Thomas DG, Greenson JK, Giordano TJ, Orringer MB, Chang AC, Beer DG, et al: Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia. 8:1062–1071. 2006. View Article : Google Scholar : PubMed/NCBI
21	Troncone G, Guerriero E, Pallante P, Berlingieri MT, Ferraro A, Del Vecchio L, Gorrese M, Mariotti E, Iaccarino A, Palmieri EA, et al: UbcH10 expression in human lymphomas. Histopathology. 54:731–740. 2009. View Article : Google Scholar : PubMed/NCBI
22	Berlingieri MT, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A, Mansueto G, Borbone E, Guerriero E, Troncone G, et al: UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer. 43:2729–2735. 2007. View Article : Google Scholar : PubMed/NCBI
23	Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, Ferraro A, Leone V, Sboner A, Barbareschi M, et al: UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 26:2136–2140. 2007. View Article : Google Scholar : PubMed/NCBI
24	Zhao L, Jiang L, Wang L, He J, Yu H, Sun G, Chen J, Xiu Q and Li B: UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer. J Cancer Res Clin Oncol. 138:1951–1961. 2012. View Article : Google Scholar : PubMed/NCBI
25	Wang C, Pan YH, Shan M, Xu M, Bao JL and Zhao LM: Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel. Int J Mol Sci. 16:4698–4712. 2015. View Article : Google Scholar : PubMed/NCBI
26	Doherty FJ, Dawson S and Mayer RJ: The ubiquitin-proteasome pathway of intracellular proteolysis. Essays Biochem. 38:51–63. 2002. View Article : Google Scholar : PubMed/NCBI
27	Summers MK, Pan B, Mukhyala K and Jackson PK: The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. Mol Cell. 31:544–556. 2008. View Article : Google Scholar : PubMed/NCBI
28	Stieglitz B, Rana RR, Koliopoulos MG, Morris-Davies AC, Schaeffer V, Christodoulou E, Howell S, Brown NR, Dikic I and Rittinger K: Structural basis for ligase-specific conjugation of linear ubiquitin chains by HOIP. Nature. 503:422–426. 2013. View Article : Google Scholar : PubMed/NCBI